Dal-OUTCOMES
A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients.
- Stadium
- klaar
- Middel
- cetp-remmer
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 1 september 2008
- Last Patient In
- -
- Last Patient Last Visit
- -
Studiedirecteur
